News Release

The roles of USP1 in Ewing sarcoma

Peer-Reviewed Publication

Impact Journals LLC

Figure 8

image: 

Figure 8. A USP1 inhibitor, ML323, activates cdc42 and inhibits Ewing sarcoma growth.

view more 

Credit: 2024 Jayabal et al.

“This study uncovered important roles for USP1 in Ewing sarcoma.”

BUFFALO, NY- February 14, 2024 – A new research paper was published in Genes & Cancer on February 5, 2024, entitled, “Roles of USP1 in Ewing sarcoma.”

Ewing sarcoma is a cancer of bone and soft tissue in children and young adults that is driven by the EWS-ETS fusion transcription factor, most commonly EWS-FLI1.

Researchers Panneerselvam Jayabal, Xiuye Ma and Yuzuru Shiio from The University of Texas Health Science Center previously reported that Ewing sarcoma harbors two populations of cells, the CD133high population displaying higher growth rate and the CD133low population displaying chemotherapy resistance. In their new study, the researchers now find that the ubiquitin-specific protease 1 (USP1) is a transcriptional target of the EWS-FLI1 fusion oncoprotein, expressed at high and low levels in the CD133high and the CD133low populations, respectively, and determines chemo-sensitivity. 

“Ubiquitin-specific protease 1 (USP1) is a deubiquitinating enzyme that plays important roles in DNA damage response.”

They also found that USP1 inhibits cdc42, increases EWS-FLI1 transcriptional output, and simulates Ewing sarcoma growth. Results show that chemo-sensitization by USP1 is independent of cdc42. A pharmacological inhibitor of USP1 was able to activate cdc42 and inhibit Ewing sarcoma growth. 

“These results uncover critical roles for USP1 in Ewing sarcoma, which regulates growth and chemo-sensitivity via distinct mechanisms.”
 

Read the full study: DOI: https://doi.org/10.18632/genesandcancer.235 

Correspondence: Yuzuru Shiio - Emails: shiio@uthscsa.edu 

Keywords: chemotherapy, Ewing sarcoma; growth, USP1

 

About Genes & Cancer: Genes & Cancer covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that directly relate to these areas of research, Genes & Cancer also aims to attract papers in the areas of genomics, drug development and systems biology.

To learn more about Genes & Cancer, visit www.genesandcancer.com and connect with us on social media:

 

For media inquiries, please contact: media@impactjournals.com.

 

Genes & Cancer Journal Office

6666 East Quaker Str., Suite 1C

Orchard Park, NY 14127

Phone: 1-212-659-5400

###


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.